Monday, September 1, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Medicine

Psilocybin Enters Gastroenterology: Pioneering Psychedelic Trial Targets Treatment-Resistant IBS

June 3, 2025
in Medicine
Reading Time: 4 mins read
0
Erin Mauney, MD, Tufts University, USA.
68
SHARES
622
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

In a groundbreaking leap for psychedelic medicine and gastroenterology, Dr. Erin E. Mauney, an assistant professor of pediatrics at Tufts University and researcher at Massachusetts General Hospital, is pioneering a clinical trial that explores the effects of psilocybin on treatment-resistant irritable bowel syndrome (IBS). This study marks an innovative convergence between mental health, neurobiology, and digestive medicine, opening new avenues for patients who have long struggled with persistent gastrointestinal symptoms unrelieved by traditional treatments.

Dr. Mauney’s clinical investigation positions psychedelic-assisted therapy within the domain of functional bowel disorders, an area historically underserved due to the complex interplay of psychological, neurological, and somatic factors. By administering two doses of psilocybin, integrated with structured therapeutic sessions before and after dosing, her trial seeks to unravel how this classic psychedelic modulates interoception—the brain’s perception of internal bodily sensations—and influences gut-brain communication pathways. Functional magnetic resonance imaging (fMRI) is leveraged to capture dynamic neurobiological changes, offering unprecedented insight into the neural circuits implicated in symptom modulation.

Central to Dr. Mauney’s hypothesis is the concept that IBS and related disorders may ensue from "somatic encoding" of early-life trauma, where adverse experiences imprint themselves on the body’s physiological systems and nervous pathways. This paradigm invites a shift beyond symptomatic treatment toward addressing root psychosomatic causes. Psilocybin, with its known capacity to disrupt entrenched neural patterns and facilitate emotional processing, could recalibrate the maladaptive neurobiological signatures that perpetuate chronic gastrointestinal distress.

The impetus for Dr. Mauney’s work began during the COVID-19 pandemic, when an intellectual curiosity sparked by Michael Pollan’s book, "How to Change Your Mind," catalyzed her engagement with the therapeutic potential of psychedelics. Leveraging her background in bacteriology and clinical pediatric gastroenterology, she integrated a translational research perspective. Notably, her mentorship under leading neuroscientists specializing in psychedelics and neurointestinal health at Massachusetts General Hospital provided critical interdisciplinary expertise that shaped the study’s methodology and theoretical framework.

Dr. Mauney emphasizes that traditional medical disciplines often maintain a "schism between mind and body," particularly evident in gastroenterology where psychological and physiological symptoms are inseparably intertwined yet frequently treated in isolation. Her research aims to bridge this divide by deploying an integrative method combining patient-reported outcomes—such as detailed abdominal pain scores—with qualitative narrative accounts and high-resolution neuroimaging data. This dual approach captures both subjective healing experiences and objective neurological correlates, potentially establishing a new model for evaluating functional somatic syndromes.

While her current trial focuses on adult subjects with severe IBS, Dr. Mauney’s pediatric background roots her broader vision in early intervention and trauma-informed care. She highlights systemic societal challenges, including childhood obesity and health inequities, particularly the insufficient alignment of public policies around nutrition, urban planning, and psychosocial support. Her research thus intersects with pressing public health priorities and raises critical questions about the long-term benefits of childhood trauma prevention on adult functional diseases.

The innovative nature of this investigation also challenges clinical paradigms by proposing that psychedelic therapy can serve as a catalyst—not merely for symptom suppression—but for facilitating profound psychological and physiological recalibration. By potentially "unlocking" somatically encoded trauma, such treatments may enable a restorative process capable of achieving sustained functional recovery. The inclusion of fMRI imaging to delineate psychedelics’ modulatory effects on brain-gut networks bolsters the mechanistic understanding necessary to transition these therapies into standard clinical practice.

Dr. Mauney’s personal philosophy deeply informs her scientific approach; she stresses the importance of cultivating authentic, compassionate relationships with patients. This ethos reflects a commitment to treating individuals as whole persons rather than isolated symptom clusters. Her insistence on persistent, meticulous research echoes the maxim "We are what we repeatedly do," symbolizing an ethos of integrity and patient-centered care that permeates her work.

Looking ahead, the scalability of psychedelic-assisted treatments is a key focus. Dr. Mauney envisions refining protocols to facilitate wider accessibility in clinical settings, thus offering hope to the millions globally with treatment-refractory IBS. As psychedelics gain increasing regulatory acceptance and enter late-stage clinical trials across multiple psychiatric and neurological conditions, her work situates gastroenterology at the cutting edge of this therapeutic renaissance.

This study also prompts broader consideration of whether other medical specialties facing treatment-resistant disorders—such as chronic pain syndromes, autoimmune conditions, or neurodevelopmental disorders—could benefit from similar integrative, trauma-informed psychedelic interventions. Dr. Mauney’s research pioneers a new frontier that transcends disciplinary boundaries, suggesting future multidisciplinary bridges between psychiatry, immunology, neurology, and internal medicine.

Published as part of the Genomic Press “Innovators & Ideas” series, this in-depth interview and report provide an insightful window into the scientists driving transformative change. By weaving rigorous scientific detail with personal reflections, this narrative exemplifies how emerging research can resonate beyond academia and capture public imagination. As the psychedelic field enters a new era, Dr. Mauney’s work epitomizes the potential for groundbreaking scientific advances to restore humanity to medicine and unlock healing where traditional approaches have faltered.

Dr. Erin Mauney’s clinical trial and accompanying research not only herald a paradigm shift in the understanding and treatment of functional gastrointestinal disorders but also illuminate the profound interconnectedness of mind and body. Her pioneering use of psilocybin as a modulator of gut-brain interactions serves as a beacon for future investigations poised to redefine how medicine approaches complex, multifaceted illnesses—offering truly holistic pathways to healing for millions worldwide.


Subject of Research: People

Article Title: Erin Mauney: Psychedelics as modulators of the gut-brain interaction

News Publication Date: 3 June 2025

Web References:
DOI link: http://dx.doi.org/10.61373/pp025k.0020

Image Credits: Erin Mauney

Keywords: psilocybin, psychedelic medicine, irritable bowel syndrome, gut-brain axis, interoception, functional gastrointestinal disorders, trauma, neuroimaging, fMRI, pediatric gastroenterology, psychedelic-assisted therapy, clinical trial

Tags: fMRI in clinical researchfunctional bowel disorders researchgut-brain communicationinnovative therapies for gastrointestinal symptomsinteroception and IBSmental health and digestive health integrationneurobiology of digestive disorderspsilocybin clinical trialpsychedelic medicine in gastroenterologypsychedelic-assisted therapysomatic encoding of traumatreatment-resistant IBS
Share27Tweet17
Previous Post

Resilience Shapes Suicidal Risk in Chinese Youth

Next Post

Multifaceted THMCB Coupling in Microbial Carbonate Precipitation

Related Posts

blank
Medicine

Bleeding Hospitalizations in Medicare Anticoagulant Users vs. Nonusers

September 1, 2025
blank
Medicine

Ethiopia’s Electronic Health System: Status and Opportunities

September 1, 2025
blank
Medicine

Novel ADC Targets Fucosyl-GM1 in Lung Cancer

September 1, 2025
blank
Medicine

Sham Acupuncture’s Varying Impact on Chronic Pain

September 1, 2025
blank
Medicine

Discovering Dasatinib Analogues to Target Mutated BCR-ABL1

September 1, 2025
blank
Medicine

Sex Differences in Substance Use Treatment Outcomes

September 1, 2025
Next Post
blank

Multifaceted THMCB Coupling in Microbial Carbonate Precipitation

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27542 shares
    Share 11014 Tweet 6884
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    956 shares
    Share 382 Tweet 239
  • Bee body mass, pathogens and local climate influence heat tolerance

    642 shares
    Share 257 Tweet 161
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    509 shares
    Share 204 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    313 shares
    Share 125 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • AI-Powered Adaptive Tutoring for Moodle: A Breakthrough
  • Bleeding Hospitalizations in Medicare Anticoagulant Users vs. Nonusers
  • Ethiopia’s Electronic Health System: Status and Opportunities
  • Novel ADC Targets Fucosyl-GM1 in Lung Cancer

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,182 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading